Incidence of Hemorrhagic Complications among Patients Treated with Thrombolytic in Erbil City, Iraq
Al- Anbar Medical Journal,
2020, Volume 16, Issue 2, Pages 35-39
Abstract
Background: Recombinant tissue-type plasminogen activator is an option of treatment forsuspected occlusive vascular thrombi and its sequel (transmural myocardial infarction, pulmonaryembolism, and ischemic stroke). The most important concern associated with those patients is thefear of hemorrhagic complications.Objectives: To evaluate the incidence and risk factors of bleeding following the use of recombinanttissue-type plasminogen activator.Materials and methods: This prospective study was conducted in the Intensive Care Units ofRoj-halat Emergency Hospital and Rizgary Teaching Hospital in Erbil city, Iraq. The durationof the study was through the period from 1st of June, 2016 to 1st of March, 2017. A convenientsample of 100 patients was selected. The patients were followed after their admission to IntensiveCare Units for 24 hours after their treatment with recombinant tissue-type plasminogen activatorto explore their complications.Results: Bleeding complication represented 10% of patients treated with recombinant tissue-typeplasminogen activator (50% for each major and minor bleeding). There was a significant associationbetween increased age of patients treated with recombinant tissue-type plasminogen activatorand bleeding (P-value = 0.01). Patients with a history of hypertension, diabetes, and smokingwere significantly associated with a bleeding complication of recombinant tissue-type plasminogenactivator (P-value <0.05).Conclusion: The incidence of bleeding among patients after treatment with recombinant tissuetype plasminogen activator in the intensive care unit was acceptable. The age, diabetes, smoking,and hypertension were risk factors for increasing the bleeding complications in subjects treatedwith recombinant tissue-type plasminogen.[1] R. Mehta and A. D. Shapiro.Plasminogen deficiency.
Haemophilia, 14(6):1261–1268, 2008.
[2] P. Gurman, O. R. Miranda, A. Nathan, C. Washington,
Y. Rosen, and N. M. Elman.Recombinant tissue plas-
minogen activators (rtpa):a review.Clin Pharmacol
Ther, 97(3):274–285, 2015.
[3] D. Kireyev, H. C. Tan, and K. K. Poh.Management
of acute st-elevation myocardial infarction:reperfusion
options.Ann Acad Med Singapore, 39:927–933, 2010.
[4] P. Goldstein and E. Wiel.Management of prehospi-
tal thrombolytic therapy in st-segment elevation acute
coronary syndrome (<12 hours).Minerva Anestesiol,
71(6):297–302, 2005.
[5] G. H. Guyatt, E. A. Akl, M. Crowther, D. D. Gutterman,
and H. J. Schunemann. Executive summary: antithrom-
botic therapy and prevention of thrombosis:American
college of chest physicians evidence-based clinical prac-
tice guidelines.Chest, 141(2):7S, 2012.
[6] G. Melandri, F. Vagnarelli, D. Calabrese, F. Semprini,
S. Nanni, and A. Branzi. Review of tenecteplase (tnkase)
in the treatment of acute myocardial infarction.Vasc.
Health Risk Manag, 5:249, 2009.
[7] S. G. Goodman and W. J. Cantor.Dripandship for
acute stsegment myocardial infarction.Pol. Arch. Med.
WEWNTRZNEJ, 119(11):726–730, 2009.
[8] J. Rther, G. A. Ford, and V. N. S. Thijs. Thrombolyt-
ics in acute ischaemic stroke: historical perspective and
future opportunities.Cerebrovasc. Dis., 35(4):313–319,
2013.
[9] A. Baratlooet al.Tissue plasminogen activator: A liter-
ature review.Arch Neurosci, 3(1):e30452, 2016.
[10] M. T. Mullen,J. M. Pisapia,S. Tilwa,S. R. Mess,
andS.C.Stein.Systematicreviewofoutcomeaf-
ter ischemic stroke due to anterior circulation occlu-
sion treated with intravenous,intra-arterial,or com-
bined intravenous+ intra-arterial thrombolysis.Stroke,
43(9):2350–2355, 2012.
[11] B. T. Batemanet al.Factors associated with in-hospital
mortality after administration of thrombolysis in acute
ischemic stroke patients:an analysis of the nationwide
inpatient sample 1999 to 2002.Stroke, 37(2):440–446,
2006.
[12] K. B. Al-Kubaisi and M. B. Al-Rikabi.The effect of
tissue plasminogen activator on the management of acute
myocardial infarction.IRAQI J. Med. Sci., page 278,
2000.
[13] N. A. N. Muhamad, Mm. E. MbBcHBAO, M. S. Azizan,
N. A. Masani, T. S. Ling, and O. T. Siang.Asscoci-ation of risk factors and its bleeding complication for
tenecteplase administered in acute myocardial infarction
(AMI).Med J Malaysia, 68(5):381, 2013.
[14] H.-H. ERLEMEIER, W. Zangemeister, L. Burmester,
J. Schofer, D.-G. MATHEY, and W. Bleifeld. Bleeding
after thrombolysis in acute myocardial infarction.Eur.
Heart J., 10(1):16–23, 1989.
[15] S. D. Berkowitzet al.Incidence and predictors of bleed-
ing after contemporary thrombolytic therapy for myocar-
dial infarction.Circulation, 95(11):2508–2516, 1997.
[16] P. Pheerawong and B. Plienthaisong. Outcome of recom-
binant tissue plasminogen activator in st-segment eleva-
tion myocardial infarction in buriram hospital.J Med As-
soc Thail Chotmaihet Thangphaet, 97(8):804–811, 2014.
[17] L. M. Brass,J. H. Lichtman,Y. Wang,J. H. Gur-
witz, M. J. Radford, and H. M. Krumholz.Intracra-
nial hemorrhage associated with thrombolytic therapy
for elderly patients with acute myocardial infarction: re-
sults from the cooperative cardiovascular project.Stroke,
31(8):1802–1811, 2000.
[18] J. S. Balami, B. A. Sutherland, and A. M. Buchan. Com-
plications associated with recombinant tissue plasmino-
gen activator therapy for acute ischaemic stroke.CNS
Neurol. Disord. Targets (Formerly Curr. Drug Targets-
CNS Neurol. Disord, 12(2):155–169, 2013.
[19] M. G. Lansberg, G. W. Albers, and C. A. C. Wijman.
Symptomatic intracerebral hemorrhage following throm-
bolytic therapy for acute ischemic stroke: a review of the
risk factors.Cerebrovasc. Dis., 24(1):1–10, 2007.
[20] P. P. De Jaegere, A. A. Arnold, A. H. Balk, and M. L.
Simoons.Intracranial hemorrhage in association with
thrombolytic therapy:incidence and clinical predictive
factors.J. Am. Coll. Cardiol., 19(2):289–294, 1992.
[21] S. B. Soumerai, T. J. McLaughlin, D. Ross-Degnan, C. L.
Christiansen, and J. H. Gurwitz. Effectiveness of throm-
bolytic therapy for acute myocardial infarction in the
elderly: cause for concern in the old-old.Arch. Intern.
Med., 162(5):561–568, 2002.
[22] A. K. BERGERet al.Primary coronary angioplasty vs
thrombolysis for the management of acute myocardial in-
farction in elderly patients.Surv. Anesthesiol, 44(3):136–
137, 2000.
[23] B. G. Angeja, A. C. Rundle, J. H. Gurwitz, J. M. Gore,
and H. V Barron.Death or nonfatal stroke in patients
with acute myocardial infarction treated with tissue plas-
minogen activator.Am. J. Cardiol., 87(5):627–630, 2001.
[24] M. Martnez-Sells, T. Datino, and H. Bueno.Influence
of reperfusion therapy on prognosis in patients aged 89
years with acute myocardial infarction.Am. J. Cardiol.,
95(10):12321234, 2005.
[25] A. Carro and J. C. Kaski. Myocardial infarction in the
elderly.ging Dis., 2(2):116, 2011
- Article View: 16
- PDF Download: 3